A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell–Mediated Tumor Elimination
- 23 June 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 23 (10) , 873-888
Abstract
Integrin α5β1 and αv cross-talk in chemotaxis, and clonogenic survival of prostate cancer cells is abrogated by a bispecific α5β1/αv antibody (BsAbα5β1/αv), which uniquely induces internalization and lysosomal degradation of target integrins. We hypothesized that the BsAbα5β1/αv inactivates pathologic mechanosignaling pathways that correlate with integrin expression from patient samples. Mechanistic studies indicate that the BsAbα5β1/αv uniquely reverses Yes-associated protein, β-catenin, and focal adhesion kinase nuclear localization compared with monospecific integrin α5β1 and αv antibody controls in basal-type androgen receptor–negative prostate cancer cells. Dual integrin αv and α5 knockdown alone phenocopied the BsAbα5β1/αv effect. Following BsAbα5β1/αv treatment, Assay for Transposase-Accessible Chromatin using sequencing studies indicated the chromatin accessibility to TEAD and AP-1 family members was markedly reduced. In vitro and in vivo RNA sequencing indicated downregulation of Myc/E2F, TGF-β, and epithelial–mesenchymal transition and upregulation of type I and II IFN transcriptomic pathways. The BsAbα5β1/αv induced CXCL10 and CCL5 cytokine secretion, immune-infiltration of tumors, and NK cell–mediated elimination of the basal-type prostate cancer xenografts in nude mice. αv integrin was highly expressed and principally correlated with the Myc signaling pathway in rapid autopsy tissue microarrays, consistent with correlative data from the SU2C metastatic castration-resistant prostate cancer and Deutsches Krebsforschungszentrum early-onset prostate cancer cohorts. These studies connect integrin signaling with the central biology of basal-type and castration-resistant prostate cancers and define a novel therapeutic strategy that controls critical immunosuppressive pathways. Implications: Dual integrin α5β1/αv targeting with a bispecific antibody represents a novel therapeutic strategy that reprograms the epigenetic and transcriptomic signatures of basal-type prostate cancer with induction of immunologic tumor control.Keywords
All Related Versions
Funding Information
- National Cancer Institute (R01CA245864)
- Pacific Northwest Prostate Cancer SPORE (P50CA97186)
- National Cancer Institute (CA163227)
This publication has 50 references indexed in Scilit:
- Human prostate cancer bone metastases have an actionable immunosuppressive microenvironmentCancer Cell, 2021
- Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerJAMA Oncology, 2021
- Chemokines and the immune response to cancerImmunity, 2021
- Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint TherapyCell, 2019
- Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical TrajectoriesCancer Cell, 2018
- YAP/TAZ at the Roots of CancerCancer Cell, 2016
- The Molecular Taxonomy of Primary Prostate CancerCell, 2015
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015
- Nuclear FAK: a New Mode of Gene Regulation from Cellular AdhesionsMolecules and Cells, 2013
- Mutant p53 Drives Invasion by Promoting Integrin RecyclingCell, 2009